טוען...
Rapid desensitization for brentuximab vedotin (Adceteris(®)) allergy: a case report
BACKGROUND: Brentuximab vedotin (BV) is an antibody–drug conjugate formed by an anti-CD30 chimeric IgG(1) conjugated with monomethyl-auristatin-E. BV targets the CD30(+) cells, which characterize Hodgkin lymphoma as well as anaplastic large cell lymphoma. Once bound to the CD30(+) cells BV exerts it...
שמור ב:
| הוצא לאור ב: | Clin Mol Allergy |
|---|---|
| Main Authors: | , , , , , , |
| פורמט: | Artigo |
| שפה: | Inglês |
| יצא לאור: |
BioMed Central
2018
|
| נושאים: | |
| גישה מקוונת: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6205792/ https://ncbi.nlm.nih.gov/pubmed/30386181 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12948-018-0100-0 |
| תגים: |
הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!
|